Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

Dr. Johnson, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute, clarifies how physicians should use the PD-L1 biomarker when prescribing checkpoint inhibitors for lung cancer

Published: 16 April 2018

Recent Videos: Lung (includes NSCLC, SCLC, Mesothelioma)

video

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Ou considers whether Tumor Mutation Burden (TMB) is a valid biomarker in determining non-small cell lung cancer (NSCLC) patients ...

video

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

Dr. Ou provides opinion on whether he would continue pemetrexed maintenance after successful treatment of a patient with carboplatin, pemetrexed, ...

video

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

Dr. Ou elaborates on the key takeaways from the IMpower150 study in non-small cell lung cancer (NSCLC) and whether the ...

video

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

Dr. Ou offers opinion on how chemotherapy should be combined with immunotherapy in the treatment of 2nd line non-small cell ...

video

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

Dr. Ou discusses outcomes from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st ...

video

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

Dr. Ou offers opinion on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and ...

video

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Levy elaborates on whether Tumor Mutation Burden (TMB) is a valid biomarker to determine those non-small cell lung cancer ...

video

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

Dr. Levy offers opinion on continuing pemextrexed maintenance after successful treatment of a non-small cell lung cancer (NSCLC) patient with ...

video

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

Dr. Levy shares key takeaways from the Impower150 study in non-small cell lung cancer (NSCLC) and whether the outcomes change ...

video

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

Dr. Levy elaborates on some of the current treatment options for non-small cell lung cancer (NSCLC) patients who progress on ...

Related Videos

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

James Hamrick, MD, on how practicing oncologists and the FDA could utilize real world evidence

video-image

James Hamrick, MD, explains how real world evidence figures into clinical trial design

video-image

James Hamrick, MD, discusses the value of real world evidence data

video-image

Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care

video-image

Ricky Newton on how COA has helped practices keep their in-office dispensing in network

video-image

Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices

video-image

Ted Okon, MBA, considers what can be done to encourage PBM transparency

video-image

Ted Okon, MBA, on what COA is doing to help community oncology practices

video-image

Ted Okon, MBA, regarding the key issues faced by community oncologists today

video-image

Ted Okon, MBA, offers his interpretation of the Practice Impact Report released at COA 2018

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Robert Rifkin, MD, tells us about biosimilar pricing and reimbursement

video-image

Robert Rifkin, MD, lists those biosimilars now approved or close to approval

video-image

Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists

video-image

Robert Rifkin, MD, on the impact of extrapolation and interchangeability on biosimilar use

video-image

Robert Rifkin, MD, tells us about the regulatory pathway for gaining FDA approval of a biosimilar

video-image

Robert Rifkin, MD, explains the key features of biosimilars

video-image

Rebecca A. Kirch, JD, explains how CMS & commercial insurers have embraced palliative care

video-image

Rebecca A. Kirch, JD, on factors that should be considered before starting a palliative care program

video-image

Rebecca A. Kirch, JD, discusses the impact of high quality palliative care programs

video-image

Ray Page, DO, PhD, on what oncology practices should be doing to advocate for their patients

video-image

Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care

video-image

Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM

video-image

Nate Brown speculates on the future of MIPS and oncology practices

video-image

Nate Brown regarding the steps a practice should take to get started on MIPS

video-image

Nate Brown explains why a practice should participate in MIPS

video-image

Miriam Atkins, MD, elaborates on what cancer patients can do to advocate for themselves

video-image

Miriam Atkins, MD, considers what COA is doing to educate patients on their cancer care

video-image

Michael Kolodziej, MD, FACP, on the legislative issues most salient to community oncologists today

video-image

Michael Kolodziej, MD, FACP, considers how the move from volume to value impacts community oncology

video-image

Mark Fendrick, MD, on cost containment strategies that work best in value-based insurance design

video-image

Mark Fendrick, MD, on designing incentives when dealing with expensive cancer therapies

video-image

Mark Fendrick, MD, considers the challenges associated with value-based insurance design

video-image

Mark Fendrick, MD, provides examples of value-based insurance design in oncology care

video-image

Mark Fendrick, MD, explains the motivation behind value-based insurance design

video-image

Michael Diaz, MD, considers what PBMs can do to help community oncology

video-image

Michael Diaz, MD, discusses what cancer patients can do to advocate for themselves

video-image

Michael Diaz, MD, shares what COA is doing to educate cancer care patients

video-image

Michael Diaz, MD, tells us about the goals of the patient initiative on Capital Hill at COA 2018

video-image

Kathy Oubre on how lobbying has helped influence the community oncology agenda

video-image

Kathy Oubre outlines some of the lobbying tactics that community oncology practices should adopt

video-image

Kathy Oubre explains why it’s important for community oncology practices to participate in lobbying

video-image

Jonathan E. Levitt, Esq. explains why oncology practices should be aware of co-pay aggregators

video-image

Jonathan E. Levitt, Esq. on the importance of PBM transparency

video-image

Jonathan E. Levitt, Esq. discusses the problems that exist between PBMs and oncology providers

video-image

Jonathan E. Levitt, Esq. provides an update on the oncology landscape from a legal perspective

video-image

Jeff Mortier explains what can be done to encourage PBM transparency

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Jeff Mortier discusses some of the issues presented at Hill Day during COA 2018

video-image

Fred Schnell, MD, compares OCM 2.0 and OCM 1.0

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Fred Schnell, MD, considers why practice transformation is often difficult in oncology

video-image

Debra Patt, MD, MPH, MBA, regarding advances in next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, considers reimbursement & coverage of CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on what community oncologists should know before prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, explains the benefits & challenges associated with prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, analyzes the logistics associated with CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on CMS’s National Coverage Determination & next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, regarding the reliability of next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, on the progress being made in next-generation sequencing

video-image

Bud Pierce, MD, describes how Oregon Oncology Specialists has evolved

video-image

Bud Pierce, MD, explains what his practice is doing to alleviate financial toxicity

video-image

Bud Pierce, MD, regarding the doctor-patient relationship in today’s oncology landscape

video-image

Brian DeLashmutt considers cost of care in hospital-based & community oncology settings

video-image

Brian DeLashmutt shares details of his own cancer care experience

video-image

Houston Holmes, MD, MBA, FACP, provides perspective on reimbursement & coverage of CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on what community oncologists should know about prescribing CAR-Ts

video-image

Houston Holmes, MD, MBA, FACP, regarding the benefits & challenges of prescribing CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on the logistics associated with CAR-T therapies

video-image

Suanne Gersdorf, FACHE, MSB, on the impact of value-based care and easing financial toxicity

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Suanne Gersdorf, FACHE, MSB, considers how EHR data can be used to improve outcomes

video-image

Suanne Gersdorf, FACHE, MSB, on how oncology practices have become more efficient in utilizing APNs

video-image

Suanne Gersdorf, FACHE, MSB, regarding the importance of embracing APNs

video-image

Harry “Mac” Barnes, MD, explains the benefits of training advanced practitioners

video-image

Harry “Mac” Barnes, MD, elaborates on the role of advanced care providers in cancer patient care